Glenmark launches cardiovascular drugs Sacubitril + Valsartan in India

The launch of Sacubitril + Valsartan has been launched under the brand name Sacu V

Glenmark Pharmaceuticals, an innovation‐driven, global pharmaceutical company, launched the sacubitril + valsartan tablets in India, for the treatment of heart failure. Marketed under the brand name ‘Sacu V’, it must be taken twice daily under a doctor’s prescription. Its approved indication is to reduce the risk of cardiovascular-related deaths and hospitalisations for patients with chronic heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF).  

Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals, said, “Heart failure is growing in India at an alarming rate; its prevalence is about 1 per cent and affects around 8-10 million individuals. With the launch of Sacu V, we are proud to bring to the patients an advanced and affordable treatment option, which has been shown to reduce the risk of cardiovascular death or heart failure hospitalisation and to improve symptoms associated with heart failure with reduced ejection fraction (HFrEF).”

The sacubitril-valsartan combination belongs to the class ARNI (Angiotensin receptor neprilysin inhibitor). These molecules have two therapeutic targets in the treatment of heart failure: 1) the natriuretic peptide (NP) system for sacubitril and 2) Renin-Angiotensin System (RAS) for valsartan. The use of sacubitril + valsartan has an established role in the treatment of patients with heart failure with reduced ejection fraction (HFrEF) and has been endorsed by the latest heart failure treatment guidelines in Europe and the US.

Glenmark’s Sacu V is priced at Rs 19 per tablet for a dose of 50mg (sacubitril 24mg + valsartan 26 mg), Rs 35 per tablet for a dose of 100 mg (sacubitril 49 mg + valsartan 51 mg), and Rs 45 per tablet for a dose of 200 mg (sacubitril 97mg + valsartan 103 mg).

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button